Progrip与ProFlor两种免固定装置在腹腔镜腹股沟疝修补术中的随机对照试验
这项随机多中心临床试验比较Progrip自固定补片与ProFlor三维动态再生支架在腹腔镜双侧腹股沟疝修补术中的效果。共150例患者随机分组,132例完成24个月随访分析。ProFlor组手术时间更短、并发症更少、术后早期疼痛更轻,且无慢性疼痛和复发,而Progrip组慢性疼痛发生率为10.8%、2例复发。
要点
- ProFlor组较Progrip组手术时间更短、并发症更少、早期疼痛更轻。
- ProFlor组无慢性疼痛发生,Progrip组慢性疼痛发生率为10.8%。
- Progrip组有2例复发,ProFlor组无复发,但需更大样本验证。
核心结论
- 两种装置用于腹腔镜双侧腹股沟疝修补均可行有效,但ProFlor支架与更少术后疼痛、无慢性疼痛及随访期无复发相关。
研究设计与样本
- 随机、多中心临床试验,纳入18-85岁临床诊断双侧原发性腹股沟疝成人患者,采用区组随机分为Progrip组或ProFlor组,随访24个月,分配对研究者和患者均未设盲。
- 2021年1月至2022年6月共150例患者接受腹腔镜TAPP修补,18例失访(ProFlor组5例,Progrip组13例),最终分析132例(ProFlor组67例,Progrip组65例)。
主要发现
- ProFlor组相比Progrip组手术时间更短、术中及术后并发症更少、术后早期疼痛更轻。
- ProFlor组患者恢复更快、更早恢复日常活动。
- ProFlor组无患者发生慢性疼痛,而Progrip组慢性疼痛发生率为10.8%。
- Progrip组有2例疝复发,ProFlor组无复发报告。
临床怎么用
- 对于腹腔镜双侧腹股沟疝修补,ProFlor支架可能减少术后疼痛、慢性疼痛和复发,但需更大样本和更长随访证实后方可常规应用。
局限性
- 分配对研究者和患者均未设盲。
- 样本量有限(最终分析132例),随访24个月,需更大样本和更长随访确认ProFlor的潜在获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TRIAL DESIGN: This randomized, multicenter clinical trial evaluates laparoscopic bilateral inguinal hernia repair outcomes by comparing the Progrip self-fixating mesh to the ProFlor 3D dynamic regenerative scaffold. METHODS: Adults aged 18-85 years with clinically diagnosed bilateral primary inguinal hernias were enrolled and randomized into two treatment groups (Progrip or ProFlor) using block randomization. Operative time, intra- and postoperative complications, recurrence rates, postoperative pain, and quality of life were assessed over a 24-month follow-up. The allocation was not blinded to investigators or patients. RESULTS: From January 2021 to June 2022, 150 patients underwent laparoscopic TAPP repair. Eighteen were lost to follow-up (5 in the ProFlor group, 13 in the Progrip group). A total of 132 patients (67 ProFlor, 65 Progrip) were analyzed. The ProFlor group demonstrated shorter operative times, fewer intra- and postoperative complications, and reduced early postoperative pain compared to the Progrip group. Patients in the ProFlor arm achieved faster recovery and earlier return to daily activities. Notably, none of the ProFlor patients experienced chronic pain, whereas 10.8% of Progrip patients developed this complication. Hernia recurrence was observed in 2 Progrip patients, while no recurrences were reported in the ProFlor™ group. CONCLUSION: In this randomized trial, both devices proved feasible and effective for laparoscopic repair of bilateral inguinal hernias. However, the ProFlor scaffold was associated with reduced postoperative pain, absence of chronic pain, and no recurrences during follow-up compared to Progrip. While these findings are encouraging, further studies with larger cohorts and longer-term follow-up are warranted to confirm the potential benefits of the ProFlor scaffold and its role in routine clinical practice. TRIAL REGISTRATION: This study was registered at ClinicalTrials.gov with number NCT06556498.
引用
- Di Buono G, Romano G, Rodolico V, et al. Progrip versus ProFlor: two fixation-free devices for laparoscopic inguinal hernia repair-the Pro/Pro study, a randomized clinical trial. Surg Endosc. 2025. PMID: 40167608. doi:10.1007/s00464-025-11680-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。